A Randomized Open Blind Control Study Assessing Clopidogrel Resistance in Iranian Patients Undergoing Percutaneous Coronary Intervention in Rajaie Heart Center

Abstract

The prevalence of response variability to clopidogrel in Iranian patients undergoing elective percutaneous coronary intervention (PCI) with stenting, impleta has not been fully investigated. We evaluated clopidogrel antiplatelet effects of 300 mg versus a 450 mg in open blind randomized clinical trial in a referral teaching hospital in Iran.